Skip to main content
. 2024 May 16;15:1415535. doi: 10.3389/fneur.2024.1415535

Figure 1.

Figure 1

Summary of key NMOSD biomarkers and their clinical utility during various stages of disease. Except where indicated, all referenced biomarkers are from serum. *Relapse prediction for serum GFAP has only been shown within <1 week preceding relapse.